Quanta Therapeutics

Quanta Therapeutics, Inc. is a biotechnology company based in the US, focused on developing innovative allosteric inhibitors targeting RAS-driven cancers, particularly KRAS mutations.Founded in 2018 and headquartered in South San Francisco, US, Quanta Therapeutics, Inc. specializes in developing targeted therapies for RAS-driven cancers. The firm was established to address critical needs in oncology, particularly targeting KRAS mutations.Quanta Therapeutics specializes in developing innovative allosteric inhibitors specifically targeting RAS-driven cancers, with a focus on KRAS mutations, which are implicated in nearly 25% of all cancers. Their primary product offerings include distinct small molecule inhibitors designed to target KRAS mutations, particularly the KRAS G12D and KRAS G12V variants.Quanta Therapeutics operates within a framework focused on partnerships and collaborations to advance its pipeline of KRAS inhibitors. The company engages in Business-to-Business (B2B) transactions with pharmaceutical companies and research institutions, which may involve licensing agreements or co-development partnerships for their proprietary compounds. Revenue generation may stem from milestones achieved during clinical development phases, as well as potential royalties on sales post-commercialization of successful products.In May 2023, Quanta Therapeutics, Inc. The company plans to develop new product offerings targeting additional KRAS mutations and expand its market presence, particularly in oncology.

1. Series D

   May 10, 2023

   Amount

   $51M

   Investors

   Locked

2. Series C

   Oct 20, 2021

   Amount

   $40M

   Investors

   Locked